Pigmented cells are derived from neural crest cells, which migrate along the peripheral nerve sheets into their specific final region. During their migration, cells progressively acquire pigment-producing capabilities, maturation, and the shape of melanocytes. These insights, along with specific clinical characteristics of melanocytic nevi, have led to new concepts of cutaneous, periocular, and iris nevogenesis. To further elucidate the specific ocular embryogenic melanoblast distribution and dissemination - that could explain the distinct distribution of uveal melanocytic neoplasms - we investigated the ocular pigmentation of dogs affected by a specific mutation called Merle, which results in either pigment- (wild type) or non-pigment- (mutated type) producing cells. Based on our observations, we propose a unifying concept of uveal pigment cell distribution and dissemination, which postulates melanoblast migration and maturation following the trigeminal V1 branch and, later, their entrance into the eye along the ciliary nerves and their finest iris branches. Our concept provides an explanation not only for the specific distribution of ocular melanocytic lesions, including uveal and iris nevi, but also for the different locations depending on the metastatic potential of the ocular melanoma. Though speculative, the higher metastatic potential of posterior uveal melanomas compared to iris melanomas may be related to a less differentiated stage in the maturation of migrating melanocytes in the posterior segment compared to the anterior segment of the eye. However, there is a need of further studies focusing on cell differentiation markers of melanocytes at different locations in the eye.

1.
Alexeev, V., K. Yoon (2006) Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol 126: 1102-1110.
2.
Cichorek, M., M. Wachulska, A. Stasiewicz, A. Tyminska (2013) Skin melanocytes: biology and development. Postepy Dermatol Alergol 30: 30-41.
3.
Cieslak, M., M. Reissmann, M. Hofreiter, A. Ludwig (2011) Colours of domestication. Biol Rev Camb Philos Soc 86: 885-899.
4.
Clark, L.A., J.M. Wahl, C.A. Rees, K.E. Murphy (2006) Retrotransposon insertion in SILV is responsible for merle patterning of the domestic dog. Proc Natl Acad Sci USA 103: 1376-1381.
5.
Cramer, S.F. (2001) Speckled lentiginous nevus (nevus spilus): the ‘roots' of the ‘melanocytic garden'. Arch Dermatol 137: 1654-1655.
6.
Dausch, D., W. Wegner, M. Michaelis, I. Reetz (1977) Ophthalmologische Befunde in einer Merlezucht. Dtsch Tierärztl Wochenschr 84: 468-475.
7.
Gleason, B.C., C.P. Crum, G.F. Murphy (2008) Expression patterns of MITF during human cutaneous embryogenesis: evidence for bulge epithelial expression and persistence of dermal melanoblasts. J Cutan Pathol 35: 615-622.
8.
Hamel, O., P. Corre, S. Ploteau, O. Armstrong, J.M. Rogez, R. Robert, A. Hamel (2012) Ciliary ganglion afferents and efferents variations: a possible explanation of postganglionic mydriasis. Surg Radiol Anat 34: 897-902.
9.
Hedan, B., S. Corre, C. Hitte, S. Dreano, T. Vilboux, T. Derrien, B. Denis, F. Galibert, M.D. Galibert, C. Andre (2006) Coat colour in dogs: identification of the merle locus in the Australian shepherd breed. BMC Vet Res 2: 9.
10.
Horikawa, T., D.A. Norris, J.J. Yohn, T. Zekman, J.B. Travers, J.G. Morelli (1995) Melanocyte mitogens induce both melanocyte chemokinesis and chemotaxis. J Invest Dermatol 104: 256-259.
11.
Huang, W.H., H.W. Wang, Q.N. Sun, H.Z. Jin, Y.H. Liu, D.L. Ma, Y.G. Zuo, H.Y. Zheng, K. Wan, Q. Jing, Y.L. Zhao (2013) A new classification of nevus of Ota. Chin Med J (Engl) 126: 3910-3914.
12.
Krohn, J., T. Froystein, O. Dahl (2008) Posterior uveal melanoma: distribution of the sites of origin and patterns of tumour extent in the ocular fundus. Br J Ophthalmol 92: 751-756.
13.
Li, W., H. Judge, E.S. Gragoudas, J.M. Seddon, K.M. Egan (2000) Patterns of tumor initiation in choroidal melanoma. Cancer Res 60: 3757-3760.
14.
Matatall, K.A., O.A. Agapova, M.D. Onken, L.A. Worley, A.M. Bowcock, J.W. Harbour (2013) BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. BMC Cancer 13: 371.
15.
May, A. (2004) Morphology of the long and short uveal nerves in the human eye. J Anat 205: 113-120.
16.
Mensink, H.W., J. Vaarwater, R.J. de Keizer, D. de Wolff-Rouendaal, C.M. Mooy, A. de Klein, D. Paridaens (2011) Chromosomal aberrations in iris melanomas. Br J Ophthalmol 95: 424-428.
17.
Mort, R.L., I.J. Jackson, E.E. Patton (2015) The melanocyte lineage in development and disease. Development 142: 1387.
18.
Nishimura, E.K. (2011) Melanocyte stem cells: a melanocyte reservoir in hair follicles for hair and skin pigmentation. Pigment Cell Melanoma Res 24: 401-410.
19.
Ostrander, E.A. (2001) The Genetics of the Dog. Oxfordshire, CAB International.
20.
Saari, M., G. Johansson (1974) Myelinated nerves of the rat iris. Acta Anat (Basel) 89: 139-144.
21.
Saida, T. (2006) Histogenesis of congenital and acquired melanocytic nevi: a unifying concept. Am J Dermatopathol 28: 377-379.
22.
Satoshi, K., K. Toshiko, S. Takao (1989) Comparative anatomy of the accessory ciliary ganglion in mammals. Anat Embryol 180: 199-205.
23.
Schünke, M., E. Schulte, U. Schuhmacher, M. Voll, K. Wesker (2006) Prometheus: LernAtlas der Anatomie - Kopf und Neuroanatomie. Stuttgart, Thieme.
24.
Schwab, C., I. Zalaudek, C. Mayer, R. Riedl, W. Wackernagel, H. Juch, B. Aigner, A.M. Brunasso, G. Langmann, E. Richtig (2015) New insights into oculodermal nevogenesis and proposal for a new iris nevus classification. Br J Ophthalmol 99: 644-649.
25.
Shields, C.L., S. Kaliki, M.N. Cohen, P.W. Shields, M. Furuta, J.A. Shields (2015) Prognosis of uveal melanoma based on race in 8,100 patients: the 2015 Doyne Lecture. Eye (Lond) 29: 1027-1035.
26.
Shields, J.A., C.L. Shields (2008) Intraocular Tumors: an Atlas and Textbook. Philadelphia, Lippincott Williams & Wilkins.
27.
Shields, C.L., J.A. Shields, H. Kiratli, P. De Potter, J.R. Cater (1995) Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmology 102: 1351-1361.
28.
Shoushtari, A.N., R.D. Carvajal (2014) GNAQ and GNA11 mutations in uveal melanoma. Melanoma Res 24: 525-534.
29.
Singh, A.D., B.E. Damato, J. Pe‘er, L.A. Murphree, J.D. Perry (2009) Essentials of Ophthalmic Oncology. Thorofare, Slack.
30.
Singh, A.D., P. De Potter, B.A. Fijal, C.L. Shields, J.A. Shields, R.C. Elston (1998) Lifetime prevalence of uveal melanoma in white patients with oculo(dermal) melanocytosis. Ophthalmology 105: 195-198.
31.
Sommer, L. (2011) Generation of melanocytes from neural crest cells. Pigment Cell Melanoma Res 24: 411-421.
32.
Theos, A.C., S.T. Truschel, G. Raposo, M.S. Marks (2005) The Silver locus product Pmel17/gp100/Silv/ME20: controversial in name and in function. Pigment Cell Res 18: 322-336.
33.
Van Raamsdonk, C.D., V. Bezrookove, G. Green, J. Bauer, L. Gaugler, J.M. O'Brien, E.M. Simpson, G.S. Barsh, B.C. Bastian (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457: 599-602.
34.
Wackernagel, M., M. Schneider, C. Mayer, G. Langmann, D. Singh (2009) Genetik des Aderhautmelanoms. Spektrum Augenheilkd 23: 319-332.
35.
Wilkie, A.L., S.A. Jordan, I.J. Jackson (2002a) Neural crest progenitors of the melanocyte lineage: coat colour patterns revisited. Development 129: 3349-3357.
36.
Wilkie, A.L., S.A. Jordan, I.J. Jackson (2002b) Neural crest progenitors of the melanocyte lineage: coat colour patterns revisited. Development 129: 3349-3357.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.